1. Clinical and neuroimaging correlates of progression of mild parkinsonian signs in community-dwelling older adults
- Author
-
Cameron Miller-Patterson, Caterina Rosano, Stephen B. Kritchevsky, Andrea L. Rosso, Robert M. Boudreau, Lenore J. Launer, Jennifer Han, and Kristine Yaffe
- Subjects
Male ,0301 basic medicine ,Aging ,Parkinson's disease ,Vascular risk ,Severity of Illness Index ,0302 clinical medicine ,80 and over ,Brain mri ,Gray Matter ,skin and connective tissue diseases ,Aged, 80 and over ,screening and diagnosis ,Diabetes ,Confounding ,Magnetic Resonance Imaging ,Detection ,Diffusion Tensor Imaging ,Diffusion tensor imaging ,Neurology ,Disease Progression ,Mild parkinsonism ,Biomedical Imaging ,Female ,Cognitive Sciences ,Independent Living ,Parkinsonian-like signs ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Demographics ,Clinical Sciences ,Mild parkinsonian signs ,Article ,03 medical and health sciences ,Parkinsonian Disorders ,Neuroimaging ,Diabetes mellitus ,Internal medicine ,medicine ,Humans ,Male gender ,Aged ,Neurology & Neurosurgery ,business.industry ,Neurosciences ,nutritional and metabolic diseases ,medicine.disease ,Brain Disorders ,4.1 Discovery and preclinical testing of markers and technologies ,030104 developmental biology ,Neurology (clinical) ,Geriatrics and Gerontology ,business ,030217 neurology & neurosurgery ,Follow-Up Studies - Abstract
Introduction Mild parkinsonian signs (MPS) are associated with morbidity. Identification of MPS progression markers may be vital for preventive management, yet has not been pursued. This study aimed to ascertain clinical/neuroimaging features predictive of MPS progression. Methods 205 participants in the Health ABC Study were included. MPS was defined using published guidelines. MPS progression was evaluated by determining UPDRS-III change between baseline and follow-up ≥2 years later. Standard brain MRI and DTI were obtained at baseline. Correlation coefficients between demographics, vascular risk factors, imaging markers, and UPDRS-III change were adjusted for follow-up time. Linear regression was used to adjust for possible confounders in the relationship between imaging markers and MPS progression. Results 30% of participants had baseline MPS. Demographics and risk factors did not differ significantly between participants with MPS (MPS+) and without MPS (MPS-). Mean follow-up time was 3.8±0.8 years. Older age, male gender, diabetes were associated with faster rate of UPDRS-III change in MPS- but not MPS+ participants. Among MPS- participants, the only imaging marker associated with faster UPDRS-III progression was higher gray matter mean diffusivity (MD), widespread in various cortico-subcortical bihemispheric regions, independent of age, gender, diabetes. No imaging features were associated with UPDRS-III change among MPS+ participants. Conclusions Lower gray matter integrity predicted MPS progression in those who did not have baseline MPS. Microstructural imaging may capture early changes related to MPS development, prior to macrostructural change. Any future management promoting gray matter preservation may inhibit MPS development.
- Published
- 2020
- Full Text
- View/download PDF